ImmuPharma (LON:IMM) Trading Up 11.2% – Still a Buy?

ImmuPharma plc (LON:IMM) shot up 11.2% during mid-day trading on Saturday . The stock traded as high as GBX 2.66 ($0.04) and last traded at GBX 2.28 ($0.03). 13,502,244 shares traded hands during mid-day trading, an increase of 102% from the average session volume of 6,691,796 shares. The stock had previously closed at GBX 2.05 ($0.03).

ImmuPharma Stock Performance

The company’s 50 day simple moving average is GBX 2.52 and its 200-day simple moving average is GBX 3.05. The firm has a market capitalization of £9.69 million, a PE ratio of -3.94 and a beta of 1.53.

ImmuPharma (LON:IMM) last issued its quarterly earnings results on Monday, May 19th. The company reported GBX (0.60) (($0.01)) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, equities research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.